Warning: Constant WP_DEBUG already defined in /home/cspmrc5/public_html/beta/wp-config.php on line 91

Warning: Constant WP_DEBUG_LOG already defined in /home/cspmrc5/public_html/beta/wp-config.php on line 92

Warning: Constant WP_DEBUG_DISPLAY already defined in /home/cspmrc5/public_html/beta/wp-config.php on line 93
2021 Annual Meeting Videos- Summer | California Society of Physical Medicine and Rehabilitation

2021 California Society of Physical Medicine and Rehabilitation Annual Meeting Part 1

Eligible for up to 6.5 AMA PRA Category 1 CreditsTM

Syllabus

 


2021 CSPM&R Annual Meeting Daily Schedule

 

1:45 – 2:15 pm

Michael Su, MD

Pharmachologic and Non-Pharmacologic Adjuncts for Stroke Recovery

 

2:15 – 3:15 pm

Chirag Vora, MD

Suboxone and Opioid Alternatives in Chronic Pain

 

3:45 – 4:45 pm

Sam Lee, MD

PM&R and Its Unique Position for Interdisciplinary Research

 

4:45 -5:45 pm

Robert Bitonte, MD, JD, LLM

Physician Retaliation

Legality and reality

8:00 – 9:00 am

Mai Ngo, MD

Acute Flaccid Myelitis and Increasing Pediatric Rehabilitation Access

 

9:00 – 10:00 am

11:00-12:00 am

Bianca Tribuzio, DO

Ultrasound and Interventional Treatment of Knee Pain

 

12:00-1:00 pm

Gabriel Barnard, MD, MS

Ketamine for Chronic Pain

 

Accreditation Statement Policy

 

The California Society of Physical Medicine and Rehabilitation is accredited by the California Medical Association (CMA) to provide continuing medical education for physicians.

This activity qualifies for up to 5.5 units of AMA PRA category I units and 4.5 units of CA DWC QME CME.

Michael Su, MD- no disclosures or conflicts

Chirag Vora, MD- no disclosures or conflicts

Sam Lee, DO- no disclosures or conflicts

Robert Bitonte, MD- no disclosures or conflicts

Mai Ngo, MD- no disclosures or conflicts

Christina Manh, MD- no disclosures or conflicts

Bianca Tribuzio, MD- no disclosures or conflicts

Gabriel Barnard, MD- no disclosures or conflicts

None of the planners for this educational
activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.